Search Results for “cancer” – Page 54 – media

New AI system for lung cancer and heart disease

Artificial intelligence is gradually being adopted by health services to assist medics with the diagnosis of serious diseases. In one new development, scientists in Oxford, U.K. have launched an AI system for heart disease.
- Source: Digital Journal
- 955
- January 15, 2018
AI heart attacks lung cancer Researches
Women who work nights face higher cancer risk

Women who regularly work the night shift in Europe and North America may face a 19 percent higher risk of cancer than those who work during the day, said a study Monday.
- Source: msn
- 574
- January 11, 2018
breast cancer cancer Researches
Cancer deaths decline again in US

The cancer death rate in 2015 was 14 percent higher in blacks than in whites, down from a peak of 33 percent in 1993.
- Source: msn
- 536
- January 9, 2018
cancer Death rates smoking
New understanding of why cancer cells move

A University of Hawai'i Cancer Center researcher has identified how some cancer cells are made to move during metastasis. The research provides a better understanding of how cancer spreads and may create new opportunities for cancer drug development.
- Source: medicalxpress
- 376
- December 28, 2017
cancer cells metastasis Researches
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. (Janssen) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
- Source: Janssen
- 484
- December 25, 2017
CRPC inhibitor New Approvals
EU OKs first-line use of Roche’s lung cancer drug Alecensa

Roche’s Alecesna has been cleared for use in Europe as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), offering a new option for patients newly diagnosed with the disease.
- Source: Pharmatimes
- 467
- December 22, 2017
Alecesna New Approvals NSCLC
Artificial Intelligence Could Help in Breast Cancer Diagnosis

Researchers say AI procedure was successful in detecting the spread of breast cancer. It’s the latest artificial intelligence innovation in the medical world.
- Source: healthline
- 640
- December 19, 2017
Artificial Intelligence breast cancer Researches
US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO® (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases, in the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 (L858R) substitution mutations). The FDA has granted TAGRISSO Priority Review status, and previously granted Breakthrough Therapy Designation for TAGRISSO in the 1st-line treatment of patients with metastatic EGFR mutation-positive (EGFRm) NSCLC.
- Source: finance.yahoo
- 606
- December 19, 2017
AstraZeneca CNS FDA New Approvals NSCLC TAGRISSO®
ODS Medical’s Innovative Device Could Revolutionize Brain Cancer Surgery

The Montreal-based startup ODS Medical is developing a handheld surgical guidance tool to improve accuracy in cancer surgery. Based on a set of advanced optical techniques, such as Raman spectroscopy, intrinsic fluorescence and diffuse reflectance spectroscopy, together with sophisticated machine learning algorithms, their laser technology measure scattered light to provide more specific information about the molecular makeup of the targeted brain tissue.
- Source: mindsofmalady
- 558
- December 18, 2017
cancer surgery Company Insight tumor
Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer

Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive (M+) advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine kinase inhibitors (TKI) – afatinib* in first-line, followed by second-line osimertinib**as part of standard clinical practice – will be analysed to determine total time on treatment.
- Source: boehringer-ingelheim
- 508
- December 14, 2017
EGFR NSCLC Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.